转移性颈部淋巴结病的快中子照射：一项RTOG随机研究的结果
Fast neutron irradiation of metastatic cervical adenopathy: the results of a randomized RTOG study.
作者信息
Griffin T W, Davis R, Laramore G E, Hussey D H, Hendrickson F R, Rodriguez-Antunez A
出版信息
Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1267-70. doi: 10.1016/0360-3016(83)90256-0.
Between 1977 and 1982, 199 evaluable patients with measurable cervical adenopathy were entered on a prospective, randomized RTOG study evaluating the use of fast neutrons in treatment of advanced, inoperable squamous cell carcinomas of the head and neck region. One hundred-eleven patients were randomized to receive mixed beam radiation therapy, and 88 were randomized to the photon control treatment. The complete response rates were 86% for mixed beam vs 75% for photons for Stage N1 nodes, 62% for mixed beam vs 48% for photons for Stage N2 nodes, and 63% for mixed beam vs 53% for photons for N3 nodes. The percents of patients remaining free of their adenopathy for two years were 78% for mixed beam vs 55% for photons for Stage N1 nodes, 39% for both mixed beam and photons for N2 nodes and 24% for mixed beam vs 13% for photons for N3 nodes. The median disease-free status was 20.3 months for mixed beam treated patients and 6.4 months for photon-treated patients. Patients who had clearance of cervical adenopathy survived significantly longer than those who did not.
在1977年至1982年期间，199例可评估的有可测量颈部淋巴结病的患者参加了一项前瞻性、随机的放射治疗肿瘤学组（RTOG）研究，该研究评估快中子在治疗晚期、不可切除的头颈部鳞状细胞癌中的应用。111例患者被随机分配接受混合束放射治疗，88例被随机分配接受光子对照治疗。对于N1期淋巴结，混合束治疗的完全缓解率为86%，光子治疗为75%；对于N2期淋巴结，混合束治疗为62%，光子治疗为48%；对于N3期淋巴结，混合束治疗为63%，光子治疗为53%。对于N1期淋巴结，混合束治疗后两年无淋巴结病的患者百分比为78%，光子治疗为55%；对于N2期淋巴结，混合束和光子治疗均为39%；对于N3期淋巴结，混合束治疗为24%，光子治疗为13%。混合束治疗患者的无病状态中位数为20.3个月，光子治疗患者为6.4个月。颈部淋巴结病清除的患者比未清除的患者存活时间显著更长。
Zotero 插件